Recent News

• 05.06.2025 - PTC 1st Quarter 2025 Financial Results
• 05.06.2025 - PTC 1st Quarter 2025 Financial Results
• 04.25.2025 - PTC Therapeutics Receives Positive CHMP Opinion for Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU)
• 04.25.2025 - PTC Therapeutics Receives Positive CHMP Opinion for Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU)
• 04.24.2025 - PTC Therapeutics to Participate at Upcoming Investor Conferences
• 04.24.2025 - PTC Therapeutics to Participate at Upcoming Investor Conferences
• 04.17.2025 - PTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results
• 04.17.2025 - PTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results
• 03.28.2025 - PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 03.28.2025 - PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Recent Filings

• 04.24.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.22.2025 - 144 Report of proposed sale of securities
• 04.17.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 04.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.02.2025 - 144 Report of proposed sale of securities
• 03.28.2025 - 8-K Current report
• 03.28.2025 - EX-99.1 EX-99.1